时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
Cancer does not simply arise—it is selected.；Long before a pathologist identifies a malignant cell, the tissue microenvironment has been conducting a silent Darwinian competition: metabolically stressed cells acquire epigenetic modifications that raise apoptotic thresholds and promote constitutive survival signaling, and those that do are enriched relative to their neighbors.
方法
The emerging observational signal is provocative: a 2026 meta-analysis of 24 observational studies enrolling nearly 4 million patients found a 30% reduction in obesity-related cancer risk (); in addition, a large retrospective cohort confirmed reduced overall cancer incidence in adults with obesity [hazard ratio (HR) 0.83; 95% confidence interval (CI), 0.76 to 0.91] ().；The most compelling recent clinical evidence comes from a retrospective cohort of 841,831 patients with breast cancer drawn from the TriNetX network, in which propensity-matched GLP-1RA users demonstrated approximately 60% lower all-cause mortality at both 5 and 10 years compared with non-users, with a large relative improvement in recurrence-free survival ().；A meta-analysis of 48 randomized controlled trials (RCTs) enrolling 94,245 participants found no effect of GLP-1RAs on obesity-related cancer incidence (, ).
核心结论
A systematic review using the hyperinsulinemic–euglycemic clamp confirmed that severe insulin resistance is present in patients with cancer relative to matched controls (mean glucose disposal rate 4.7 vs. 7.5 mg/kg/min; p < 0.01), with limited evidence suggesting that this adaptation may precede clinical diagnosis ().；SAM availability works separately: when SAM is limiting, EHMT1/2 preferentially preserve H3K9me1 while higher-order di- and trimethylation decline, so SAM depletion does not itself add to H3K9me2 ().；The emerging observational signal is provocative: a 2026 meta-analysis of 24 observational studies enrolling nearly 4 million patients found a 30% reduction in obesity-related cancer risk (); in addition, a large retrospective cohort confirmed reduced overall cancer incidence in adults with obesity [hazard ratio (HR) 0.83; 95% confidence interval (CI), 0.76 to 0.91] (). ‖ 结论：Neither this manuscript nor the available evidence establishes that GLP-1 receptor agonists prevent recurrence or resistance, but prospective trials enrolling metabolically high-risk patients with cancer endpoints and adequate follow-up are needed to resolve the tension between the observational signal and the randomized null.
局限
We do not offer this as a replacement for clonal evolution, of which the selection of pre-existing clones is a constituent process, but as a proposed contributor to the pre-treatment resistance heterogeneity on which subsequent therapeutic pressure acts.；Neither this manuscript nor the available evidence establishes that GLP-1 receptor agonists prevent recurrence or resistance, but prospective trials enrolling metabolically high-risk patients with cancer endpoints and adequate follow-up are needed to resolve the tension between the observational signal and the randomized null.
对本项目的价值
★☆☆☆☆ 相关范围内，作为背景与横向对照收录。
全文来源
PMC JATS 全文（正文 15,973 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Metabolic oncology: clonal selection and the pre-existing origins of cancer resistance.
- 期刊与标识：Front Oncol · PMID 42964081 · DOI 10.3389/fonc.2026.1951576
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。